Hedwig M. Blommestein

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Nature · 2024 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16

Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study

Hedwig M. Blommestein, S. Verelst, Peter C. Huijgens et al. · Annals of Hematology · 2012 · 53 citations

Medicine, Hematology, Pharmacoeconomics +12

Long‐term Outcomes in Patients With Multiple Myeloma

S. Verelst, Hedwig M. Blommestein, Saskia de Groot et al. · HemaSphere · 2018 · 51 citations · Full text

Medicine, Hematology, Pharmacology +14

Changes in survival in de novo metastatic cancer in an era of new medicines

Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein et al. · JNCI Journal of the National Cancer Institute · 2023 · 51 citations · Full text

Medicine, Biostatistics, Gastrointestinal Oncology +16